Brief: AB Science Provides Update On Application For Conditional Marketing Authorisation Of Masitinib In ALS
29/05/2024 18:01
May 29 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR
CONDITIONAL
MARKETING AUTHORISATION OF MASITINIB IN ALS
* AB SCIENCE SA - CHMP OF EMA ADOPTED A TRENDING TOWARD A
NEGATIVE
OPINION ON APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION
OF MASITINIB
* AB SCIENCE SA - CHMP IS EXPECTED TO ADOPT A FORMAL OPINION
ON
MAA AT ITS NEXT MEETING, WHICH WILL BE HELD JUNE 24-27, 2024
Source text for Eikon: ID:nGNX2JgyRQ
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041